← All stocks

Revolution Medicines, Inc.

RVMD Scheduled selling only
CIK 0001628171 #590 in the set updated 21 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$43.63M
$21.75M on a plan · $21.88M straight out of an exercise
Sold at will
$0.00
0 of 41 sales
Net
−$43.63M
$0.00 against sales at will

By person

18 insiders · 41 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Kelsey Stephen Michael
See Remarks
$19.83M (10) scheduled
−$19.83M
286,307
0.1336%
$57.06M
+7.8%
Kim Lorence H.
Director
$14.97M (14) scheduled
−$14.97M
1,191
0.0006%
$237.37K
−98.3%
Mancini Anthony
See Remarks
$3.51M (7) scheduled
−$3.51M
42,116
0.0196%
$8.39M
−22.9%
GOLDSMITH MARK A
See Remarks
$2.79M (2) scheduled
−$2.79M
376,190
0.1755%
$74.98M
+68.0%
Horn Margaret A
Chief Operating Officer
$989.61K (2) scheduled
−$989.61K
149,680
0.0698%
$29.83M
+12.0%
Anders Jack
Chief Financial Officer
$807.51K (2) scheduled
−$807.51K
119,216
0.0556%
$23.76M
+18.9%
Cislini Jeff
SVP & General Counsel
$670.63K (2) scheduled
−$670.63K
52,541
0.0245%
$10.47M
+13.6%
Sandler Alan B.
Chief Development Officer
$67.94K (2) scheduled
−$67.94K
52,868
0.0247%
$10.54M
−0.6%
Borisy Alexis
Director
2,340,075
1.09%
$466.38M
+0.2%
Schroeder Thilo
Director
760,869
0.3550%
$151.64M
Wang Xiaolin
See Remarks
116,063
0.0541%
$23.13M
+33.9%
Wei Lin
Chief Medical Officer
101,366
0.0473%
$20.20M
−10.7%
Horning Sandra
Director
97,765
0.0456%
$19.48M
+4.6%
Borellini Flavia
Director
26,215
0.0122%
$5.22M
+19.8%
ANDERSON ELIZABETH M
Director
24,406
0.0114%
$4.86M
+21.6%
Patel Sushil
Director
21,656
0.0101%
$4.32M
+8.6%
Weber Barbara
Director
13,065
0.0061%
$2.60M
−28.5%
Clyburn Frank
Director
10,929
0.0051%
$2.18M
+57.7%
Insider
Date
Role
Action
Shares
Price
Amount
Anders Jack
16 Sep 2026
Chief Financial Officer
Sold on a plan
3,992
$199.30
$795.62K
Anders Jack
16 Sep 2026
Chief Financial Officer
Sold on a plan
61
$195.00
$11.90K
Cislini Jeff
16 Sep 2026
SVP & General Counsel
Sold on a plan
3,314
$199.30
$660.49K
Cislini Jeff
16 Sep 2026
SVP & General Counsel
Sold on a plan
52
$195.01
$10.14K
GOLDSMITH MARK A
16 Sep 2026
See Remarks
Sold on a plan
13,775
$199.30
$2.75M
GOLDSMITH MARK A
16 Sep 2026
See Remarks
Sold on a plan
213
$195.01
$41.54K
Horn Margaret A
16 Sep 2026
Chief Operating Officer
Sold on a plan
4,891
$199.30
$974.79K
Horn Margaret A
16 Sep 2026
Chief Operating Officer
Sold on a plan
76
$195.01
$14.82K
Kelsey Stephen Michael
16 Sep 2026
See Remarks
Sold on a plan
5,484
$199.30
$1.09M
Kelsey Stephen Michael
16 Sep 2026
See Remarks
Sold on a plan
85
$195.01
$16.58K
Sandler Alan B.
16 Sep 2026
Chief Development Officer
Sold on a plan
336
$199.30
$66.97K
Sandler Alan B.
16 Sep 2026
Chief Development Officer
Sold on a plan
5
$194.96
$974.79
Mancini Anthony
16 Sep 2026
See Remarks
Sold on a plan
1,747
$199.30
$348.18K
Mancini Anthony
16 Sep 2026
See Remarks
Sold on a plan
27
$195.05
$5.27K
Kim Lorence H.
8 Sep 2026
Director
Sold on a plan indirect
371
$212.27
$78.75K
Kim Lorence H.
8 Sep 2026
Director
Sold on a plan indirect
3,844
$211.36
$812.46K
Kim Lorence H.
8 Sep 2026
Director
Sold on a plan indirect
4,730
$210.50
$995.68K
Kim Lorence H.
8 Sep 2026
Director
Sold on a plan indirect
2,853
$209.56
$597.87K
Kim Lorence H.
8 Sep 2026
Director
Sold on a plan indirect
3,587
$208.55
$748.08K
Kim Lorence H.
8 Sep 2026
Director
Sold on a plan indirect
999
$207.33
$207.12K
Kim Lorence H.
8 Sep 2026
Director
Sold on a plan indirect
706
$206.60
$145.86K
Kim Lorence H.
31 Aug 2026
Director
Sold on a plan indirect
625
$206.15
$128.85K
Kim Lorence H.
31 Aug 2026
Director
Sold on a plan indirect
2,128
$205.19
$436.64K
Kim Lorence H.
31 Aug 2026
Director
Sold on a plan indirect
7,271
$204.35
$1.49M
Kim Lorence H.
31 Aug 2026
Director
Sold on a plan indirect
26,160
$203.55
$5.32M
Kim Lorence H.
31 Aug 2026
Director
Sold on a plan indirect
12,919
$202.48
$2.62M
Kim Lorence H.
31 Aug 2026
Director
Sold on a plan indirect
6,597
$201.47
$1.33M
Kim Lorence H.
31 Aug 2026
Director
Sold on a plan indirect
300
$200.56
$60.17K

What was left out

Form 4 filings counted 13
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 28
Sales straight out of an exercise 13
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 101,894
History held since 14 Feb 2020